Dupilumab boosts esophageal distensibility, diameter for EoE in ‘first time’ showing

CHICAGO — Dupilumab significantly improved esophageal distensibility and diameter in eosinophilic esophagitis at 24 weeks, alongside marked gains in endoscopic and histologic disease outcomes, data presented at Digestive Disease Week showed.“Esophageal strictures and narrowing, also called fibrostenosis, are commonly seen in EoE, and traditionally are treated with esophageal